Definium Therapeutics, Inc.
DFTX
Kedudukan dalam Saham
#3515
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Harga Saham
$35.62
Modal Pasaran
$4.79B
Perubahan (1 hari)
0.36%
Perubahan (1 tahun)
236.05%
Negara
US
Perdagangan Definium Therapeutics, Inc. (DFTX)
Kategori
Healthcare
Sejarah harga saham bagi Definium Therapeutics, Inc. (DFTX)
Harga penutupan tertinggi: $10.57 pada 2024-04-01
Harga penutupan terendah: $4.87 pada 2020-03-01
Harga penutupan terendah: $4.87 pada 2020-03-01
Sejarah harga saham Definium Therapeutics, Inc. dari 2020 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2024 | 205.04% |
| 2023 | 33.53% |
| 2022 | -89.94% |
| 2021 | -40.17% |
| 2020 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $532.09 | 24.77% |
US
|
|
| $236.63 | 781.30% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $889.94 | 9.31% |
NL
|
|
| $291.42 | 2.39% |
BE
|
